Skip to content

Prices

The Case Against These Two Hot COVID-19 Vaccine Stocks

The two biotechs that are the focus of today’s article have been hot this year, with shares of both having experienced triple-digit growth. The reason? Their respective COVID-19 vaccine development programs, which have moved at lightning-fast speed.